If your gastroenterologist has prescribed Entyvio for ulcerative colitis and you carry an Aetna plan, the short answer is that Aetna does cover vedolizumab, the active ingredient in Entyvio, but coverage is not automatic. Aetna, a CVS Health company, treats Entyvio as a specialty biologic that requires prior authorization, and it spells out the medical necessity criteria in a published Clinical Policy Bulletin. Understanding how that bulletin works, what your plan expects you to have tried first, and how to document your case can be the difference between a smooth approval and a frustrating denial. This guide walks through Aetna's coverage mechanics for Entyvio in ulcerative colitis and what to verify in your own plan documents.
What Entyvio Is and Why Aetna Covers It
Entyvio, the brand name for vedolizumab, is a gut-selective biologic that binds to the alpha-4 beta-7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1, an action that limits inflammation in the gastrointestinal tract without broad systemic immune suppression, according to the FDA prescribing information for Entyvio. The same label confirms it is approved in adults for moderately to severely active ulcerative colitis. Standard dosing is a 300 mg intravenous infusion at weeks 0, 2, and 6, then every eight weeks, with a 108 mg subcutaneous maintenance option once every two weeks for patients who respond to the initial infusions. Because it carries a recognized indication, Aetna includes vedolizumab among covered drugs for UC.
Aetna's Clinical Policy Bulletin for Vedolizumab
Aetna documents its requirements in Clinical Policy Bulletin 0885 for vedolizumab, which is publicly viewable. The bulletin confirms that Entyvio requires precertification, meaning your prescriber must obtain approval before the first infusion is billed. It also specifies that for ulcerative colitis the medication must be prescribed by or in consultation with a gastroenterologist. For continued coverage beyond the induction phase, the bulletin asks for evidence that you are achieving or maintaining remission or a positive clinical response, which it defines through measures such as reduced stool frequency, reduced rectal bleeding, lower fecal calprotectin or C-reactive protein, and improved endoscopic appearance scored with tools like the Mayo score. Reading this bulletin tells you exactly what Aetna's reviewers will be looking for.
Step Therapy and What You Must Try First
Whether you face step therapy depends on which arm of your benefit handles the drug. Aetna's pharmacy benefit, managed through CVS Caremark, applies its own specialty criteria. The Aetna non-Medicare specialty pharmacy policy for Entyvio states that approval can be granted for moderately to severely active UC when a member has had an inadequate response, intolerance, or contraindication to at least one conventional therapy option, or when the member has previously received another biologic or targeted synthetic drug. Conventional options listed include mesalamine, corticosteroids, and immunomodulators such as azathioprine or mercaptopurine. This positioning is consistent with the AGA living guideline on moderate-to-severe ulcerative colitis, which lists vedolizumab among recommended therapies and suggests infliximab or vedolizumab over adalimumab for biologic-naive patients. Step therapy expectations vary by plan, so confirm the exact prior trials your contract requires.
Building the Medical-Necessity Case
The evidence Aetna's reviewers want maps closely to what a thorough chart already contains. Entyvio has substantial trial support for UC: in the GEMINI 1 trial, 47.1 percent of vedolizumab-treated patients achieved a clinical response at week 6 compared with 25.5 percent on placebo, and 41.8 percent in the every-eight-week maintenance group were in clinical remission at week 52 versus 15.9 percent on placebo. That efficacy record supports a medical-necessity argument when paired with your own documented history. Your prior authorization is strongest when it shows dated records of the conventional or biologic therapies you tried, the reason each was stopped, and objective markers of active disease such as calprotectin, CRP, or endoscopy findings. Organized, dated documentation is what turns the policy criteria above into an approval rather than a request for more information.
If Aetna Denies Coverage
A denial is not the end of the process. Under federal rules, you have the right to a full internal appeal when a health plan refuses to cover a service, and the right to an external review by an independent third party if that internal appeal fails. According to CMS guidance on appealing health plan decisions, you generally have up to 180 days from the denial notice to file an internal appeal, and consumers who reach external review have historically prevailed against the insurer in roughly 45 percent of cases. If your health could be seriously harmed by waiting, you can request an expedited appeal that must be decided far faster than the standard timeline. A strong appeal restates the medical-necessity case, attaches a letter from your gastroenterologist, and addresses the specific reason Aetna cited in its denial.
Verifying Your Own Plan
Clinical Policy Bulletins describe Aetna's general standards, but your individual plan controls the specifics of your coverage, including whether Entyvio falls under the medical or pharmacy benefit, the tier it occupies, and your share of the cost. Those details determine your out-of-pocket exposure and which prior authorization pathway applies. Read your summary of benefits and the formulary attached to your plan, and call the member services number on your card to confirm precertification requirements before your first infusion is scheduled. Asking your prescriber's office or the infusion center to confirm benefits in advance can prevent surprise denials. Knowing that Aetna covers vedolizumab is the starting point; confirming how your specific plan applies that coverage is what protects you from an unexpected bill.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.